Description

Ranolazine

• Class of medications: Non-traditional antianginal (weak direct vasodilator)
• Proven antianginal medication in patients with symptomatic coronary heart disease.
• Safe and effective option as monotherapy or as add-on therapy to reduce anginal symptoms in patients with chronic stable angina.
• Significantly improves total exercise duration and time to angina compared with placebo

• Acts as metabolic modulator exhibiting no or minimal adverse hemodynamic effects.
• Effective as an antiarrhythmic agent showing a reduced frequency of clinically significant arrhythmias (73.7%) compared with the placebo group (83.1%).